prednisone has been researched along with Minimal Disease, Residual in 77 studies
Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We observed a rapid decrease in minimal residual disease on molecular assessment with an MMR of P190-BCR-ABL/ABL = 0." | 5.46 | Ponatinib-Induced Graft-versus-Host Disease/Graft-versus-Leukemia Effect in a Patient with Philadelphia-Positive Acute Lymphoblastic Leukemia without the T315I Mutation Relapsing after Allogeneic Transplant. ( Bossio, S; De Stefano, L; Gentile, M; Greco, R; Mazzone, C; Morabito, F; Morelli, R; Musolino, C; Palummo, A; Petrungaro, A; Recchia, AG; Uccello, G; Vigna, E, 2017) |
| "Standard chemotherapy with melphalan-prednisone or a combination of alkylating agents has not extended the overall survival of patients with multiple myeloma during the last 30 years and strictly defined complete remissions (CR) are exceedingly rare." | 4.79 | Hematopoietic stem cell transplants for multiple myeloma. ( Barlogie, B; Bracy, D; Desikan, KR; Jagannath, S; Siegel, D; Tricot, G; Vesole, DH, 1996) |
| "The protocol included minimal residual disease (MRD) analysis at two different time-points (TP), that is, at the end of induction IA and consolidation IB, and a modulation in post-consolidation intensity according to MRD." | 3.01 | Adolescent and young adult acute lymphoblastic leukemia. Final results of the phase II pediatric-like GIMEMA LAL-1308 trial. ( Candoni, A; Canichella, M; Cavalli, M; Chiaretti, S; Conter, V; D'Aloisio, M; De Propris, MS; Elia, L; Fazi, P; Foà, R; Guarini, A; Luppi, M; Martino, B; Messina, M; Moleti, ML; Piciocchi, A; Starza, ID; Testi, AM; Vignetti, M; Vitale, A, 2021) |
| "Patients with locally advanced prostate cancer have an increased risk of cancer recurrence and mortality." | 2.90 | Evaluation of Intense Androgen Deprivation Before Prostatectomy: A Randomized Phase II Trial of Enzalutamide and Leuprolide With or Without Abiraterone. ( Bubley, GJ; Calagua, C; Chang, P; Chang, SL; Ellis, WJ; Harshman, LC; Kibel, AS; Lin, DW; Lis, R; McKay, RR; Montgomery, B; Pienta, KJ; Ross, AE; Taplin, ME; Trinh, QD; Wagner, AA; Xie, W; Ye, H; Zhang, Z, 2019) |
| "Minimal residual disease was evaluated by a EuroMRD standardized real-time PCR approach after 3 and 6 cycles of the induction therapy." | 2.87 | Potential loss of prognostic significance of minimal residual disease assessment after R-CHOP-based induction in elderly patients with mantle cell lymphoma in the era of rituximab maintenance. ( Belada, D; Blahovcova, P; Forsterova, K; Fronkova, E; Janikova, A; Kalinova, M; Klener, P; Kodet, R; Mejstrikova, E; Mocikova, H; Prochazka, V; Pytlik, R; Salek, D; Simkovic, M; Trka, J; Trneny, M; Vaskova, M, 2018) |
| "Persistence of chemoresistant minimal residual disease (MRD) plasma cells (PCs) is associated with inferior survival in multiple myeloma (MM)." | 2.82 | Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance. ( Alignani, D; Barcena, P; Barlogie, B; Blade, J; Burgos, L; Corchete, LA; De Arriba, F; Echeveste, MA; Epstein, J; García-Sanz, R; Gironella, M; Gonzalez, Y; Hernandez, MT; Johnson, SK; Lahuerta, JJ; Maiso, P; Mateos, MV; Ocio, EM; Orfao, A; Oriol, A; Paiva, B; Palomera, L; Puig, N; Rodriguez, I; San Miguel, JF; Sanchez, ML; Vidriales, MB, 2016) |
| "Induction therapy for childhood acute lymphoblastic leukemia (ALL) traditionally includes prednisone; yet, dexamethasone may have higher antileukemic potency, leading to fewer relapses and improved survival." | 2.82 | Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000. ( Aricò, M; Attarbaschi, A; Barisone, E; Bartram, CR; Basso, G; Beier, R; Biondi, A; Caruso, R; Cazzaniga, G; Conter, V; Greiner, J; Harbott, J; Kremens, B; Kulozik, AE; Lo Nigro, L; Locatelli, F; Mann, G; Möricke, A; Niggli, F; Parasole, R; Ratei, R; Rössig, C; Schrappe, M; Silvestri, D; Stanulla, M; Valsecchi, MG; von Stackelberg, A; Zimmermann, M, 2016) |
| "The value of minimal residual disease (MRD) in multiple myeloma (MM) has been more frequently investigated in transplant-eligible patients than in elderly patients." | 2.82 | Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients. ( Arana, P; Bargay, J; Bladé, J; Cabrera, C; Cedena, MT; Cordon, L; Echeveste, MA; Encinas, C; Flores-Montero, J; Gironella, M; Gonzalez, Y; Gutierrez, NC; Hernandez, MT; Lahuerta, JJ; Martin, J; Martín-Ramos, ML; Martinez, R; Martinez-Lopez, J; Mateos, MV; Ocio, EM; Orfao, A; Oriol, A; Paiva, B; Puig, N; Rosiñol, L; San Miguel, JF; Teruel, AI; Van Dongen, JJ; Vidriales, MB, 2016) |
| "The level of minimal residual disease during remission induction is the most important prognostic indicator in patients with acute lymphoblastic leukaemia (ALL)." | 2.80 | Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study. ( Bhojwani, D; Bowman, WP; Campana, D; Cheng, C; Coustan-Smith, E; Downing, JR; Evans, WE; Gruber, TA; Inaba, H; Jeha, S; Leung, WH; Pei, D; Pui, CH; Relling, MV; Ribeiro, RC; Rubnitz, JE; Sandlund, JT, 2015) |
| "The detection of minimal residual disease (MRD) via molecular genetic methods provides - in comparison with conventional clinical and biological parameters - much more sensitive approaches to monitor individual treatment response." | 2.78 | [Molecular genetic detection of minimal residual disease (MRD) in children with acute lymphoblastic leukemia]. ( Bartram, CR; Koehler, R, 2013) |
| "Treatment of both Hodgkin's disease (HD) and high-grade non-Hodgkin's lymphoma (HG-NHL) with bulky presentation at diagnosis frequently results in residual masses detected radiologically." | 2.68 | Monitoring bulky mediastinal disease with gallium-67, CT-scan and magnetic resonance imaging in Hodgkin's disease and high-grade non-Hodgkin's lymphoma. ( Babini, L; Barbieri, E; Battista, G; Bendandi, M; Canini, R; Fanti, S; Frezza, G; Gherlinzoni, F; Gozzetti, A; Merla, E; Monetti, N; Pisi, P; Rimondi, MR; Tura, S; Zinzani, PL; Zompatori, M, 1996) |
| "The prognosis of childhood acute lymphoblastic leukemia (ALL) is optimistic with a 5-year event-free survival (EFS) rate of 70-85%." | 1.62 | Reduced intensity of early intensification does not increase the risk of relapse in children with standard risk acute lymphoblastic leukemia - a multi-centric clinical study of GD-2008-ALL protocol. ( Chen, HQ; Fang, JP; Li, CG; Li, CK; Li, JQ; Li, XY; Lin, YD; Liu, RY; Luo, XQ; Sun, X; Sun, XF; Wu, XD; Xu, HG, 2021) |
| "Although childhood acute lymphoblastic leukemia (ALL) is characterized by high remission rates, there are still patients who experience poor response to therapy or toxic effects due to intensive treatment." | 1.48 | Clinical utility of miR-143/miR-182 levels in prognosis and risk stratification specificity of BFM-treated childhood acute lymphoblastic leukemia. ( Avgeris, M; Baka, M; Drakaki, I; Gourgiotis, D; Kossiva, L; Marmarinos, A; Piatopoulou, D; Pourtsidis, A; Scorilas, A; Xagorari, M, 2018) |
| "We observed a rapid decrease in minimal residual disease on molecular assessment with an MMR of P190-BCR-ABL/ABL = 0." | 1.46 | Ponatinib-Induced Graft-versus-Host Disease/Graft-versus-Leukemia Effect in a Patient with Philadelphia-Positive Acute Lymphoblastic Leukemia without the T315I Mutation Relapsing after Allogeneic Transplant. ( Bossio, S; De Stefano, L; Gentile, M; Greco, R; Mazzone, C; Morabito, F; Morelli, R; Musolino, C; Palummo, A; Petrungaro, A; Recchia, AG; Uccello, G; Vigna, E, 2017) |
| "Prednisone response has been confirmed to be still great prognostic value and PPR children patients have poor outcomes generally." | 1.42 | [Prognostic Value of Prednisone Response in CCLG-ALL 2008]. ( An, WB; Chang, LX; Liu, TF; Ren, YY; Wan, Y; Zhang, JL; Zhu, XF; Zou, Y, 2015) |
| "The prognosis of acute lymphoblastic leukemia is poorer in adults than in children." | 1.39 | Risk group assignment differs for children and adults 1-45 yr with acute lymphoblastic leukemia treated by the NOPHO ALL-2008 protocol. ( Abrahamsson, J; Åsberg, A; Bernell, P; Birgens, H; Griškevičius, L; Hallböök, H; Heyman, M; Holm, MS; Hulegårdh, E; Jónsson, OG; Klausen, TW; Marquart, HV; Nielsen, OJ; Quist-Paulsen, P; Schmiegelow, K; Taskinen, M; Toft, N; Vaitkeviciene, G; Vettenranta, K, 2013) |
| "Today, relapses have become relatively rare events in ALL although, because of the frequency of ALL, they are still a significant cause of death in children and adolescents." | 1.39 | ALL-REZ BFM--the consecutive trials for children with relapsed acute lymphoblastic leukemia. ( Eckert, C; Henze, G; v Stackelberg, A, 2013) |
| "Based on the treatment results of 300 Hodgkin lymphoma patients the authors formulated the basic approaches for radiation treatment in ABVD and BEACOPP-21 chemotherapy regimens recipients." | 1.38 | [The optimal total focal radiotherapy dosage after first-line chemotherapy in patients with Hodgkin lymphoma]. ( Datsenko, PV; Evstikheev, ÉV; Golub, SV; Gombolevskiĭ, VA; Ivashin, AV; Pan'shin, GA; Sotnikov, VM, 2012) |
| "Acute lymphoblastic leukemia (ALL) with distinct fusion transcripts has unique clinical features." | 1.38 | Clinical features, early treatment responses, and outcomes of pediatric acute lymphoblastic leukemia in China with or without specific fusion transcripts: a single institutional study of 1,004 patients. ( Cui, L; Gao, C; Jiao, Y; Li, WJ; Li, ZG; Liu, SG; Wu, MY; Yue, ZX; Zhao, W; Zhao, XX, 2012) |
| "We retrospectively estimated the minimal residual disease in the bone marrow (BM) and the testis by detection of clone-specific T-cell receptor rearrangement of leukemic cells." | 1.35 | Detection of submicroscopic disease in the bone marrow and unaffected testis of a child with T-cell acute lymphoblastic leukemia who experienced "isolated" testicular relapse. ( Arima, K; Hasegawa, D; Hori, T; Hosoya, R; Imamura, T; Kato, I; Kitagawa, Y; Manabe, A; Ogawa, C; Takahashi, H; Takusagawa, A; Tsurusawa, M, 2009) |
| "Philadelphia chromosome positive (Ph(+)) acute lymphoblastic leukemia (ALL) includes at least one-quarter of all adults with ALL." | 1.33 | Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. ( Ottmann, OG; Wassmann, B, 2005) |
| "Minimal residual disease was monitored by qualitative and real-time quantitative PCR." | 1.33 | Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma. ( Astolfi, M; Boccadoro, M; Bodoni, CL; De Marco, F; Drandi, D; Gianni, AM; Guidetti, A; Ladetto, M; Magni, M; Mantoan, B; Matteucci, P; Pagliano, G; Ricca, I; Tarella, C; Zanni, M, 2006) |
| "Up to 80% of pediatric patients with acute lymphoblastic leukemia (ALL) can be cured if intensive therapy is applied." | 1.32 | Evolution of BFM trials for childhood ALL. ( Schrappe, M, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 10 (12.99) | 18.2507 |
| 2000's | 25 (32.47) | 29.6817 |
| 2010's | 35 (45.45) | 24.3611 |
| 2020's | 7 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Ferrari, LC | 1 |
| Rivas, MM | 1 |
| Navickas, AB | 1 |
| Dick, H | 1 |
| Mela Osorio, MJ | 1 |
| Agamennoni, L | 1 |
| Rey, IH | 1 |
| Carnelutto, NE | 1 |
| Cazap, N | 1 |
| Castro, MB | 1 |
| Aranguren, PN | 1 |
| Fischman, LA | 1 |
| Yupanki, ML | 1 |
| Milone, JH | 1 |
| Fernández, II | 1 |
| Moirano, MM | 1 |
| Belli, CB | 1 |
| Pedrosa, F | 1 |
| Coustan-Smith, E | 3 |
| Zhou, Y | 1 |
| Cheng, C | 2 |
| Pedrosa, A | 1 |
| Lins, MM | 1 |
| Pedrosa, M | 1 |
| Lucena-Silva, N | 1 |
| Ramos, AML | 1 |
| Vinhas, E | 1 |
| Rivera, GK | 2 |
| Campana, D | 3 |
| Ribeiro, RC | 3 |
| Mussolin, L | 1 |
| Lovisa, F | 1 |
| Gallingani, I | 1 |
| Cavallaro, E | 1 |
| Carraro, E | 1 |
| Damanti, CC | 1 |
| Vinti, L | 1 |
| Sala, A | 1 |
| Micalizzi, C | 2 |
| Santoro, N | 1 |
| Piglione, M | 1 |
| Cellini, M | 1 |
| Buffardi, S | 1 |
| Buldini, B | 1 |
| D'Amore, ESG | 1 |
| Biffi, A | 1 |
| Pillon, M | 1 |
| Huang, SJ | 1 |
| Gerrie, AS | 1 |
| Young, S | 1 |
| Tucker, T | 1 |
| Bruyere, H | 1 |
| Hrynchak, M | 1 |
| Galbraith, P | 1 |
| Al Tourah, AJ | 1 |
| Dueck, G | 1 |
| Noble, MC | 1 |
| Ramadan, KM | 1 |
| Tsang, P | 1 |
| Hardy, E | 1 |
| Sehn, L | 1 |
| Toze, CL | 1 |
| Zawitkowska, J | 1 |
| Lejman, M | 1 |
| Romiszewski, M | 1 |
| Matysiak, M | 1 |
| Ćwiklińska, M | 1 |
| Balwierz, W | 1 |
| Owoc-Lempach, J | 1 |
| Kazanowska, B | 1 |
| Derwich, K | 1 |
| Wachowiak, J | 1 |
| Niedźwiecki, M | 1 |
| Adamkiewicz-Drożyńska, E | 1 |
| Trelińska, J | 1 |
| Młynarski, W | 1 |
| Kołtan, A | 1 |
| Wysocki, M | 1 |
| Tomaszewska, R | 1 |
| Szczepański, T | 1 |
| Płonowski, M | 1 |
| Krawczuk-Rybak, M | 1 |
| Urbańska-Rakus, J | 1 |
| Machnik, K | 1 |
| Ociepa, T | 1 |
| Urasiński, T | 1 |
| Mizia-Malarz, A | 1 |
| Sobol-Milejska, G | 1 |
| Karolczyk, G | 1 |
| Kowalczyk, J | 1 |
| Testi, AM | 2 |
| Canichella, M | 1 |
| Vitale, A | 1 |
| Piciocchi, A | 1 |
| Guarini, A | 2 |
| Starza, ID | 1 |
| Cavalli, M | 1 |
| De Propris, MS | 1 |
| Messina, M | 1 |
| Elia, L | 1 |
| Moleti, ML | 1 |
| Martino, B | 1 |
| Luppi, M | 1 |
| D'Aloisio, M | 1 |
| Candoni, A | 1 |
| Conter, V | 3 |
| Fazi, P | 1 |
| Vignetti, M | 1 |
| Chiaretti, S | 1 |
| Foà, R | 2 |
| Li, XY | 1 |
| Li, JQ | 1 |
| Luo, XQ | 1 |
| Wu, XD | 1 |
| Sun, X | 1 |
| Xu, HG | 1 |
| Li, CG | 1 |
| Liu, RY | 1 |
| Sun, XF | 1 |
| Chen, HQ | 1 |
| Lin, YD | 1 |
| Li, CK | 1 |
| Fang, JP | 1 |
| Petrungaro, A | 1 |
| Gentile, M | 1 |
| Mazzone, C | 1 |
| Greco, R | 1 |
| Uccello, G | 1 |
| Recchia, AG | 1 |
| De Stefano, L | 1 |
| Bossio, S | 1 |
| Palummo, A | 1 |
| Morelli, R | 1 |
| Musolino, C | 1 |
| Morabito, F | 2 |
| Vigna, E | 1 |
| Schrappe, M | 10 |
| Bleckmann, K | 1 |
| Zimmermann, M | 5 |
| Biondi, A | 5 |
| Möricke, A | 6 |
| Locatelli, F | 3 |
| Cario, G | 2 |
| Rizzari, C | 2 |
| Attarbaschi, A | 5 |
| Valsecchi, MG | 3 |
| Bartram, CR | 4 |
| Barisone, E | 2 |
| Niggli, F | 4 |
| Niemeyer, C | 2 |
| Mann, G | 4 |
| Ziino, O | 1 |
| Schäfer, B | 1 |
| Panzer-Grümayer, R | 2 |
| Beier, R | 3 |
| Parasole, R | 2 |
| Göhring, G | 1 |
| Ludwig, WD | 5 |
| Casale, F | 1 |
| Schlegel, PG | 1 |
| Basso, G | 5 |
| Ng, AK | 2 |
| Yahalom, J | 1 |
| Goda, JS | 1 |
| Constine, LS | 1 |
| Pinnix, CC | 1 |
| Kelsey, CR | 1 |
| Hoppe, B | 1 |
| Oguchi, M | 1 |
| Suh, CO | 1 |
| Wirth, A | 1 |
| Qi, S | 1 |
| Davies, A | 2 |
| Moskowitz, CH | 1 |
| Laskar, S | 1 |
| Li, Y | 1 |
| Mauch, PM | 2 |
| Specht, L | 1 |
| Illidge, T | 2 |
| Piatopoulou, D | 1 |
| Avgeris, M | 1 |
| Drakaki, I | 1 |
| Marmarinos, A | 1 |
| Xagorari, M | 1 |
| Baka, M | 1 |
| Pourtsidis, A | 1 |
| Kossiva, L | 1 |
| Gourgiotis, D | 1 |
| Scorilas, A | 1 |
| Zheng, Y | 1 |
| Cai, YW | 1 |
| Fu, QC | 1 |
| Wang, Q | 1 |
| Ji, XQ | 1 |
| Cai, LL | 1 |
| Fuhrmann, S | 1 |
| Schabath, R | 2 |
| Kunz, JB | 1 |
| Kulozik, AE | 3 |
| Karawajew, L | 2 |
| Ratei, R | 4 |
| Klener, P | 1 |
| Fronkova, E | 1 |
| Kalinova, M | 1 |
| Belada, D | 1 |
| Forsterova, K | 1 |
| Pytlik, R | 1 |
| Blahovcova, P | 1 |
| Simkovic, M | 1 |
| Salek, D | 1 |
| Mocikova, H | 1 |
| Prochazka, V | 1 |
| Janikova, A | 1 |
| Vaskova, M | 1 |
| Mejstrikova, E | 1 |
| Kodet, R | 1 |
| Trka, J | 1 |
| Trneny, M | 1 |
| McKay, RR | 1 |
| Ye, H | 1 |
| Xie, W | 1 |
| Lis, R | 1 |
| Calagua, C | 1 |
| Zhang, Z | 1 |
| Trinh, QD | 1 |
| Chang, SL | 1 |
| Harshman, LC | 1 |
| Ross, AE | 1 |
| Pienta, KJ | 1 |
| Lin, DW | 1 |
| Ellis, WJ | 1 |
| Montgomery, B | 1 |
| Chang, P | 1 |
| Wagner, AA | 1 |
| Bubley, GJ | 1 |
| Kibel, AS | 1 |
| Taplin, ME | 1 |
| Toft, N | 1 |
| Birgens, H | 1 |
| Abrahamsson, J | 1 |
| Bernell, P | 1 |
| Griškevičius, L | 1 |
| Hallböök, H | 1 |
| Heyman, M | 1 |
| Holm, MS | 1 |
| Hulegårdh, E | 1 |
| Klausen, TW | 1 |
| Marquart, HV | 1 |
| Jónsson, OG | 1 |
| Nielsen, OJ | 1 |
| Quist-Paulsen, P | 1 |
| Taskinen, M | 1 |
| Vaitkeviciene, G | 1 |
| Vettenranta, K | 1 |
| Åsberg, A | 1 |
| Schmiegelow, K | 1 |
| Datsenko, PV | 1 |
| Pan'shin, GA | 1 |
| Sotnikov, VM | 1 |
| Ivashin, AV | 1 |
| Evstikheev, ÉV | 1 |
| Golub, SV | 1 |
| Gombolevskiĭ, VA | 1 |
| Koehler, R | 1 |
| Henze, G | 1 |
| v Stackelberg, A | 1 |
| Eckert, C | 1 |
| Ravandi, F | 1 |
| Jorgensen, JL | 1 |
| Thomas, DA | 1 |
| O'Brien, S | 1 |
| Garris, R | 1 |
| Faderl, S | 1 |
| Huang, X | 1 |
| Wen, S | 1 |
| Burger, JA | 1 |
| Ferrajoli, A | 1 |
| Kebriaei, P | 1 |
| Champlin, RE | 1 |
| Estrov, Z | 1 |
| Challagundla, P | 1 |
| Wang, SA | 1 |
| Luthra, R | 1 |
| Cortes, JE | 1 |
| Kantarjian, HM | 1 |
| Williams, ME | 1 |
| Koh, K | 1 |
| Fossat, C | 1 |
| Roussel, M | 1 |
| Arnoux, I | 1 |
| Asnafi, V | 1 |
| Brouzes, C | 1 |
| Garnache-Ottou, F | 1 |
| Jacob, MC | 1 |
| Kuhlein, E | 1 |
| Macintyre-Davi, E | 1 |
| Plesa, A | 1 |
| Robillard, N | 1 |
| Tkaczuk, J | 1 |
| Ifrah, N | 1 |
| Dombret, H | 1 |
| Béné, MC | 1 |
| Baruchel, A | 1 |
| Garand, R | 1 |
| Pui, CH | 2 |
| Pei, D | 1 |
| Jeha, S | 1 |
| Bowman, WP | 2 |
| Sandlund, JT | 2 |
| Rubnitz, JE | 2 |
| Inaba, H | 1 |
| Bhojwani, D | 1 |
| Gruber, TA | 1 |
| Leung, WH | 1 |
| Downing, JR | 1 |
| Evans, WE | 1 |
| Relling, MV | 1 |
| Kriz, J | 2 |
| Reinartz, G | 1 |
| Dietlein, M | 2 |
| Kobe, C | 2 |
| Kuhnert, G | 1 |
| Haverkamp, H | 1 |
| Haverkamp, U | 1 |
| Engenhart-Cabillic, R | 1 |
| Herfarth, K | 1 |
| Lukas, P | 1 |
| Schmidberger, H | 1 |
| Staar, S | 2 |
| Hegerfeld, K | 1 |
| Baues, C | 1 |
| Engert, A | 3 |
| Eich, HT | 3 |
| Ren, YY | 1 |
| Zou, Y | 2 |
| Chang, LX | 1 |
| An, WB | 1 |
| Wan, Y | 2 |
| Zhang, JL | 1 |
| Liu, TF | 1 |
| Zhu, XF | 1 |
| Borowitz, MJ | 2 |
| Wood, BL | 1 |
| Devidas, M | 2 |
| Loh, ML | 1 |
| Raetz, EA | 1 |
| Salzer, WL | 1 |
| Nachman, JB | 1 |
| Carroll, AJ | 2 |
| Heerema, NA | 1 |
| Gastier-Foster, JM | 1 |
| Willman, CL | 2 |
| Dai, Y | 1 |
| Winick, NJ | 1 |
| Hunger, SP | 2 |
| Carroll, WL | 2 |
| Larsen, E | 1 |
| Wei, W | 1 |
| Chen, X | 1 |
| Chang, L | 1 |
| An, W | 1 |
| Liu, T | 1 |
| Yang, W | 1 |
| Chen, Y | 1 |
| Guo, Y | 1 |
| Zhu, X | 1 |
| Paiva, B | 2 |
| Corchete, LA | 1 |
| Vidriales, MB | 2 |
| Puig, N | 2 |
| Maiso, P | 1 |
| Rodriguez, I | 1 |
| Alignani, D | 1 |
| Burgos, L | 1 |
| Sanchez, ML | 1 |
| Barcena, P | 1 |
| Echeveste, MA | 2 |
| Hernandez, MT | 2 |
| García-Sanz, R | 1 |
| Ocio, EM | 2 |
| Oriol, A | 2 |
| Gironella, M | 2 |
| Palomera, L | 1 |
| De Arriba, F | 1 |
| Gonzalez, Y | 2 |
| Johnson, SK | 1 |
| Epstein, J | 1 |
| Barlogie, B | 2 |
| Lahuerta, JJ | 2 |
| Blade, J | 2 |
| Orfao, A | 2 |
| Mateos, MV | 2 |
| San Miguel, JF | 2 |
| Stanulla, M | 3 |
| Cazzaniga, G | 2 |
| Aricò, M | 2 |
| Silvestri, D | 1 |
| Lo Nigro, L | 2 |
| Kremens, B | 1 |
| Greiner, J | 1 |
| Harbott, J | 2 |
| Caruso, R | 1 |
| von Stackelberg, A | 1 |
| Rössig, C | 1 |
| Chen, R | 1 |
| Sanchez, J | 1 |
| Rosen, ST | 1 |
| Cedena, MT | 1 |
| Arana, P | 1 |
| Cordon, L | 1 |
| Flores-Montero, J | 1 |
| Gutierrez, NC | 1 |
| Martín-Ramos, ML | 1 |
| Martinez-Lopez, J | 1 |
| Teruel, AI | 1 |
| Rosiñol, L | 1 |
| Martinez, R | 2 |
| Cabrera, C | 1 |
| Martin, J | 1 |
| Bargay, J | 1 |
| Encinas, C | 1 |
| Van Dongen, JJ | 2 |
| Chaganti, S | 1 |
| Barrington, S | 1 |
| Mckay, P | 1 |
| Linton, K | 1 |
| Cwynarski, K | 1 |
| McMillan, A | 1 |
| Stern, S | 1 |
| Peggs, K | 1 |
| Cai, JY | 1 |
| Xue, HL | 1 |
| Chen, J | 1 |
| Shen, SH | 1 |
| Pan, C | 1 |
| Wang, X | 1 |
| Zhou, M | 1 |
| Tang, YJ | 1 |
| Gao, YJ | 1 |
| Wang, JM | 1 |
| Tang, JY | 1 |
| Ceriani, L | 1 |
| Martelli, M | 1 |
| Gospodarowicz, MK | 1 |
| Ricardi, U | 1 |
| Ferreri, AJ | 1 |
| Chiappella, A | 1 |
| Stelitano, C | 1 |
| Balzarotti, M | 1 |
| Cabrera, ME | 1 |
| Cunningham, D | 1 |
| Zinzani, PL | 2 |
| Giovanella, L | 1 |
| Johnson, PW | 1 |
| Zucca, E | 1 |
| Paganin, M | 1 |
| Zecca, M | 1 |
| Fabbri, G | 1 |
| Polato, K | 1 |
| Franklin, J | 1 |
| Markova, J | 1 |
| Lohri, A | 1 |
| Amthauer, H | 2 |
| Klutmann, S | 1 |
| Knapp, WH | 1 |
| Zijlstra, JM | 1 |
| Bockisch, A | 1 |
| Weckesser, M | 1 |
| Lorenz, R | 1 |
| Schreckenberger, M | 1 |
| Bares, R | 1 |
| Mueller, RP | 1 |
| Fuchs, M | 1 |
| Borchmann, P | 1 |
| Schicha, H | 1 |
| Diehl, V | 2 |
| Dworzak, MN | 2 |
| Schumich, A | 1 |
| Printz, D | 1 |
| Pötschger, U | 1 |
| Husak, Z | 1 |
| Gaipa, G | 1 |
| Gadner, H | 4 |
| Arima, K | 1 |
| Hasegawa, D | 1 |
| Ogawa, C | 1 |
| Kato, I | 1 |
| Imamura, T | 1 |
| Takusagawa, A | 1 |
| Takahashi, H | 1 |
| Kitagawa, Y | 1 |
| Hori, T | 1 |
| Tsurusawa, M | 1 |
| Manabe, A | 1 |
| Hosoya, R | 1 |
| Pichler, H | 1 |
| Teigler-Schlegel, A | 1 |
| Nebral, K | 1 |
| König, M | 1 |
| Inthal, A | 1 |
| Krehan, D | 1 |
| Janousek, D | 1 |
| Strehl, S | 1 |
| Haas, OA | 1 |
| Larsen, EL | 1 |
| Linda, SB | 1 |
| Blach, L | 1 |
| Pullen, DJ | 1 |
| Shuster, J | 1 |
| Winick, N | 1 |
| Camitta, BM | 1 |
| Lauten, M | 1 |
| Meissner, B | 1 |
| Odenwald, E | 1 |
| Riehm, H | 2 |
| Munger, CM | 1 |
| Hegde, GV | 1 |
| Weisenburger, DD | 1 |
| Vose, JM | 1 |
| Joshi, SS | 1 |
| Halasz, LM | 1 |
| Jacene, HA | 1 |
| Catalano, PJ | 1 |
| Van den Abbeele, AD | 2 |
| Lacasce, A | 1 |
| Gao, C | 1 |
| Zhao, XX | 1 |
| Li, WJ | 1 |
| Cui, L | 1 |
| Zhao, W | 1 |
| Liu, SG | 1 |
| Yue, ZX | 1 |
| Jiao, Y | 1 |
| Wu, MY | 1 |
| Li, ZG | 1 |
| Tutor, O | 2 |
| Díaz, MA | 3 |
| Ramírez, M | 1 |
| Algara, P | 2 |
| Madero, L | 3 |
| Martínez, P | 3 |
| Lanciotti, M | 1 |
| Rossi, V | 1 |
| Di Martino, D | 1 |
| Masera, G | 2 |
| Liu, JK | 1 |
| Kan, P | 1 |
| Schmidt, MH | 1 |
| Hara, S | 1 |
| Yokote, T | 1 |
| Akioka, T | 1 |
| Oka, S | 1 |
| Yamano, T | 1 |
| Tsuji, M | 1 |
| Hanafusa, T | 1 |
| Ottmann, OG | 1 |
| Wassmann, B | 1 |
| Bibb, J | 1 |
| Hromas, R | 1 |
| Rabinowitz, I | 1 |
| Breit, S | 1 |
| Flohr, T | 1 |
| Tolle, G | 1 |
| Happich, M | 1 |
| Muckenthaler, MU | 1 |
| Ladetto, M | 1 |
| Magni, M | 1 |
| Pagliano, G | 1 |
| De Marco, F | 1 |
| Drandi, D | 1 |
| Ricca, I | 1 |
| Astolfi, M | 1 |
| Matteucci, P | 1 |
| Guidetti, A | 1 |
| Mantoan, B | 1 |
| Bodoni, CL | 1 |
| Zanni, M | 1 |
| Boccadoro, M | 1 |
| Gianni, AM | 1 |
| Tarella, C | 1 |
| Bornhauser, BC | 1 |
| Bonapace, L | 1 |
| Lindholm, D | 1 |
| Niggli, FK | 1 |
| Schäfer, BW | 1 |
| Bourquin, JP | 1 |
| Gossmann, A | 1 |
| Bredenfeld, H | 1 |
| Hansemann, K | 1 |
| Skripnitchenko, R | 1 |
| Brillant, C | 1 |
| Pfistner, B | 1 |
| Müller, RP | 1 |
| Jakacki, RI | 1 |
| Zeltzer, PM | 1 |
| Boyett, JM | 2 |
| Albright, AL | 1 |
| Allen, JC | 1 |
| Geyer, JR | 1 |
| Rorke, LB | 1 |
| Stanley, P | 1 |
| Stevens, KR | 1 |
| Wisoff, J | 1 |
| Sica, S | 1 |
| Salutari, P | 1 |
| Di Mario, A | 1 |
| D'Onofrio, G | 1 |
| Etuk, B | 1 |
| Leone, G | 1 |
| Omura, GA | 1 |
| Vogler, WR | 1 |
| Martelo, O | 1 |
| Gordon, DS | 1 |
| Bartolucci, AA | 1 |
| Tricot, G | 1 |
| Jagannath, S | 1 |
| Vesole, DH | 1 |
| Bracy, D | 1 |
| Desikan, KR | 1 |
| Siegel, D | 1 |
| Zompatori, M | 1 |
| Bendandi, M | 1 |
| Battista, G | 1 |
| Fanti, S | 1 |
| Barbieri, E | 1 |
| Gherlinzoni, F | 1 |
| Rimondi, MR | 1 |
| Frezza, G | 1 |
| Pisi, P | 1 |
| Merla, E | 1 |
| Gozzetti, A | 1 |
| Canini, R | 1 |
| Monetti, N | 1 |
| Babini, L | 1 |
| Tura, S | 2 |
| Redei, I | 1 |
| Mangan, KF | 1 |
| Ming, PL | 1 |
| Mullaney, MT | 1 |
| Rao, PN | 1 |
| Goldberg, SL | 1 |
| Klumpp, TR | 1 |
| Dibenedetto, SP | 1 |
| Mayer, SP | 1 |
| Rovera, G | 1 |
| Schilirò, G | 1 |
| Hagenbeek, A | 1 |
| Carde, P | 1 |
| Meerwaldt, JH | 1 |
| Somers, R | 1 |
| Thomas, J | 1 |
| De Bock, R | 1 |
| Raemaekers, JM | 1 |
| van Hoof, A | 1 |
| De Wolf-Peeters, C | 1 |
| van Glabbeke, M | 1 |
| Tutor-Ureta, O | 1 |
| Stroszczynski, C | 1 |
| Hosten, N | 1 |
| Oellinger, J | 1 |
| Spahn, G | 1 |
| Bittner, RC | 1 |
| Hierholzer, J | 1 |
| Felix, R | 1 |
| Panzer-Grümayer, ER | 2 |
| Schneider, M | 1 |
| Panzer, S | 1 |
| Fasching, K | 1 |
| Frohlich, DE | 1 |
| Chen, JL | 1 |
| Neuberg, D | 1 |
| Kehoe, KM | 1 |
| Liao, Z | 1 |
| Strom, EA | 1 |
| Buzdar, AU | 1 |
| Singletary, SE | 1 |
| Hunt, K | 1 |
| Allen, PK | 1 |
| McNeese, MD | 1 |
| Ruano, D | 1 |
| Garcia-Sanchez, F | 1 |
| Sancho, J | 1 |
| Hancock, ML | 1 |
| Behm, FG | 1 |
| Raimondi, SC | 1 |
| Colombat, P | 1 |
| Cornillet, P | 1 |
| Deconinck, E | 1 |
| Tourani, JM | 1 |
| Gardembas, M | 1 |
| Delain, M | 1 |
| Abgrall, JF | 1 |
| Kootz, C | 1 |
| Milpied, N | 1 |
| Horning, SJ | 1 |
| Negrin, RS | 1 |
| Hoppe, RT | 1 |
| Rosenberg, SA | 1 |
| Chao, NJ | 1 |
| Long, GD | 1 |
| Brown, BW | 1 |
| Blume, KG | 1 |
| Rambaldi, A | 1 |
| Lazzari, M | 1 |
| Manzoni, C | 1 |
| Carlotti, E | 1 |
| Arcaini, L | 1 |
| Baccarani, M | 1 |
| Barbui, T | 1 |
| Bernasconi, C | 1 |
| Dastoli, G | 1 |
| Fuga, G | 1 |
| Gamba, E | 1 |
| Gargantini, L | 1 |
| Gattei, V | 1 |
| Lauria, F | 1 |
| Lazzarino, M | 1 |
| Mandelli, F | 1 |
| Morra, E | 1 |
| Pulsoni, A | 1 |
| Ribersani, M | 1 |
| Rossi-Ferrini, PL | 1 |
| Rupolo, M | 1 |
| Zagonel, V | 1 |
| Zaja, F | 1 |
| Zinzani, P | 1 |
| Reato, G | 1 |
| Galimberti, S | 1 |
| Marasca, R | 1 |
| Caracciolo, F | 1 |
| Fazzi, R | 1 |
| Papineschi, F | 1 |
| Benedetti, E | 1 |
| Guerrini, F | 1 |
| Oliva, E | 1 |
| Di Renzo, N | 1 |
| Federico, M | 1 |
| Petrini, M | 1 |
| Torelli, G | 1 |
| Willemse, MJ | 1 |
| Seriu, T | 1 |
| Hettinger, K | 1 |
| d'Aniello, E | 1 |
| Hop, WC | 1 |
| Kamps, WA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| ALL-BFM 2000 Multi-Center Study for the Treatment of Children and Adolescents With Acute Lymphoblastic Leukemia[NCT00430118] | Phase 3 | 4,559 participants (Actual) | Interventional | 2000-07-31 | Completed | ||
| AIEOP LLA 2000 Multicenter Study for the Diagnosis and Treatment of Childhood Acute Lymphoblastic Leukemia[NCT00613457] | Phase 3 | 2,039 participants (Actual) | Interventional | 2000-09-30 | Completed | ||
| A Phase II Randomized Study of Enzalutamide+Leuprolide Versus Enzalutamide+Leuprolide+Abiraterone Acetate+Prednisone as Neoadjuvant Therapy for HIgh-Risk Prostate Cancer Undergoing Prostatectomy[NCT02268175] | Phase 2 | 75 participants (Actual) | Interventional | 2014-10-31 | Completed | ||
| Ponatinib Plus Reduced-intensity Chemotherapy in the First-line Treatment of Adult Patients With Ph-positive Acute Lymphoblastic Leukemia[NCT04554459] | Phase 2 | 32 participants (Anticipated) | Interventional | 2021-02-16 | Active, not recruiting | ||
| Total XV - Total Therapy Study XV for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia[NCT00137111] | Phase 3 | 501 participants (Actual) | Interventional | 2000-07-08 | Completed | ||
| High Risk B-Precursor Acute Lymphoblastic Leukemia (ALL)[NCT00075725] | Phase 3 | 3,154 participants (Actual) | Interventional | 2003-12-29 | Completed | ||
| A National, Open-label, Multicenter, Randomized, Comparative Phase IIb Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd)[NCT01237249] | Phase 2 | 250 participants (Actual) | Interventional | 2011-02-28 | Completed | ||
| A Perspective, Single Center Study of the MRD-tailored Therapy in Patients With Newly Diagnosed Multiple Myeloma With Persistent Minimal Residual Disease After Initial Treatment[NCT06109233] | 80 participants (Anticipated) | Observational | 2023-12-30 | Not yet recruiting | |||
| A Multicentre, Randomized Phase III Study of Thalidomide Maintenance Treatment in Patients With Diffuse Large B-cell Lymphoma[NCT03016000] | Phase 3 | 226 participants (Anticipated) | Interventional | 2017-07-26 | Recruiting | ||
| Phase 2 Study Evaluating the Efficacy of Rituximab Plus Modified VPDL for Newly Diagnosed CD20-Positive Adult Acute Lymphoblastic Leukemia[NCT01429610] | Phase 2 | 78 participants (Actual) | Interventional | 2011-11-30 | Active, not recruiting | ||
| ALinC 17: Protocol for Patients With Newly Diagnosed High Risk Acute Lymphoblastic Leukemia (ALL) - Evaluation of the Augmented BFM Regimen: A Phase III Study[NCT00005603] | Phase 3 | 276 participants (Actual) | Interventional | 2000-03-31 | Completed | ||
| "MIRO (Molecularly Oriented Immuno - Radio -Therapy): Multicenter Phase II Study for the Treatment of the Molecular Basis of Stage I / II Follicular Lymphoma With Local Radiotherapy With / Without Ofatumumab"[NCT02710643] | Phase 2 | 110 participants (Actual) | Interventional | 2014-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
PSA nadir is the lowest PSA level recorded during neoadjuvant therapy. (NCT02268175)
Timeframe: PSA was assessed at baseline and every cycle during neoadjuvant therapy (up to 24 weeks).
| Intervention | ng/mL (Median) |
|---|---|
| ARM 1 | 0.03 |
| ARM 2 | 0.02 |
pCR is defined as the absence of morphologically identifiable carcinoma in the radical prostatectomy (RP) specimen. (NCT02268175)
Timeframe: after RP approximately 24 weeks from study entry
| Intervention | Participants (Count of Participants) |
|---|---|
| ARM 1 | 5 |
| ARM 2 | 2 |
pCR is defined as the absence of morphologically identifiable carcinoma in the radical prostatectomy (RP) specimen. MRD is defined as the largest cross-sectional dimension of residual tumor measuring NCT02268175)
Timeframe: after RP approximately 24 weeks from study entry
| Intervention | percentage of participants (Number) |
|---|---|
| ARM 1 | 30 |
| ARM 2 | 16 |
RCB was analyzed using radical prostatectomy (RP) tissue. The largest area of tumor was measured by ruler and the longest tumor dimension in this area was used as the dimension for calculation. (NCT02268175)
Timeframe: after RP approximately 24 weeks from study entry
| Intervention | cm (Median) |
|---|---|
| ARM 1 | 0.03 |
| ARM 2 | 0.05 |
"White blood cell (leukocytes) counts in peripheral blood by Complete Blood Count~Measurement: Percentage change of leukemia cells from baseline" (NCT00137111)
Timeframe: Immediately before the methotrexate infusion and three days after subsequent infusion
| Intervention | Percent change (Mean) |
|---|---|
| 4 hr | -44 |
| 24 hr | -50 |
CCR was measured from end of week 56 therapy to the date of first treatment failure of any kind (relapse, death, lineage switch, or second malignancy) or to the last date of follow-up. Measurement was determined by Kaplan-Meyer estimate. (NCT00137111)
Timeframe: Median follow up time (range) 4.5 (1 to 7.8) years
| Intervention | Percentage of participants (Number) |
|---|---|
| Patients With High Risk of CNS Relapse | 92.2 |
Children were randomly assigned to receive initial single-agent treatment with HDMTX (1g/m^2) as either a 24-hour infusion or a 4-hour infusion and the outcome measure was the accumulation of MTXPG in leukemia cells. (NCT00137111)
Timeframe: 42 hours after start of high dose methotrexate infusion (HDMTX)
| Intervention | pmol/1,000,000,000 cells (Mean) |
|---|---|
| 4 hr | 1688 |
| 24 hr | 2521 |
EFS was measured from the start of on-study to the date of first treatment failure of any kind (relapse, death, lineage switch, or second malignancy) or to the last date of follow-up. Failure to enter remission was considered an event at time zero. Measurement was determined by Kaplan-Meyer estimate. (NCT00137111)
Timeframe: Median follow-up time (range) 5.6 (1.3 to 8.9) years
| Intervention | Percentage of Participants (Number) |
|---|---|
| Total Therapy | 87.3 |
Prednisolone sensitivity was measured in primary leukemia cells from bone marrow collected at diagnosis. Expression of CASP1 was determined by HG-U133A microarray. Values given are gene expression values, and the unit is arbitrary units (AU) defined as scaled fluorescence measured on microarray. (NCT00137111)
Timeframe: Pre-treatment
| Intervention | arbitrary units (Median) | |
|---|---|---|
| Prednisolone-sensitive cells | Prednisolone-resistant cells | |
| Total Therapy | 341.3 | 447.9 |
Prednisolone sensitivity was measured in primary leukemia cells from bone marrow collected at diagnosis. Expression of NLRP3 was determined by HG-U133A microarray. Values given are gene expression values, and the unit is arbitrary units (AU) defined as scaled fluorescence measured on microarray. (NCT00137111)
Timeframe: Pre-treatment
| Intervention | arbitrary units (Median) | |
|---|---|---|
| Prednisolone-sensitive cells | Prednisolone-resistant cells | |
| Total Therapy | 41.2 | 110.7 |
Detection of MRD at end of induction where positive MRD was defined as one or more leukemic cell per 10,000 mononuclear bone-marrow cells (>=0.01%). (NCT00137111)
Timeframe: End of Induction (Day 46 MRD measurement)
| Intervention | participants (Number) | |
|---|---|---|
| Negative <0.01% | Positive >= 0.01% | |
| Total Therapy | 390 | 102 |
Event Free Probability. (NCT00075725)
Timeframe: 5 years
| Intervention | percentage of participants (Number) |
|---|---|
| Dexamethasone and Capizzi Methotrexate Patients < 10 Years | 83.2 |
| Dexamethasone, High Dose Methotrexate (Non Randomly Assigned) | 81.6 |
| Dexamethasone & Capizzi Methotrexate Patients => 10 Years Old | 69.1 |
| Dexamethasone, High Dose Methotrexate (IM) < 10 Years | 91.2 |
| Prednisone, Capizzi Methotrexate <10 Years | 82.1 |
| Prednisone, Capezzi Methotrexate >= 10 Years | 73.5 |
| Predisone and High Dose Methotrexate < 10 Yrs Old | 80.8 |
| Prenisone and High Dose Methotrexate >=10 Years | 75.8 |
| Dexamethasone, High Dose Methotrexate (IM) >= 10 Years | 77.0 |
| Prenisone, Capezzi Methotrexate (Down's Syndrome) | 61.8 |
| Dexamethasone, Capizzi Methotrexate Down Syndrome (Non Random) | 44.4 |
Bone marrow status is defined as: M1: < 5% lymphoblasts; M2: 5-25% lymphoblasts; M3: > 25% lymphoblasts. Bone marrow MRD status is defined as positive with >= 0.1 detectable leukemia cells, and negative with < 0.1 detectable leukemia cells. (NCT00075725)
Timeframe: Day 29
| Intervention | participants (Number) |
|---|---|
| Dexamethasone and Capizzi Methotrexate Patients < 10 Years | 182 |
| Dexamethasone, High Dose Methotrexate (Non Randomly Assigned) | 72 |
| Dexamethasone & Capizzi Methotrexate Patients => 10 Years Old | 198 |
| Dexamethasone, High Dose Methotrexate (IM) < 10 Years | 188 |
| Prednisone, Capizzi Methotrexate <10 Years | 195 |
| Prednisone, Capezzi Methotrexate >= 10 Years | 471 |
| Prednisone and High Dose Methotrexate < 10 Yrs Old | 190 |
| Prednisone and High Dose Methotrexate >=10 Years | 479 |
| Dexamethasone, High Dose Methotrexate (IM) >= 10 Years | 208 |
| Prednisone, Capezzi Methotrexate (Down's Syndrome) | 25 |
| Dexamethasone, Capizzi Methotrexate Down Syndrome (Non Random) | 3 |
| Prednisone and High Dose Methotrexate (Non Randomly Assigned) | 18 |
Bone marrow status is defined as: M1: < 5% lymphoblasts; M2: 5-25% lymphoblasts; M3: > 25% lymphoblasts. Bone marrow MRD status is defined as positive with >= 0.1 detectable leukemia cells, and negative with < 0.1 detectable leukemia cells. (NCT00075725)
Timeframe: Day 29
| Intervention | participants (Number) |
|---|---|
| Dexamethasone and Capizzi Methotrexate Patients < 10 Years | 26 |
| Dexamethasone, High Dose Methotrexate (Non Randomly Assigned) | 12 |
| Dexamethasone & Capizzi Methotrexate Patients => 10 Years Old | 43 |
| Dexamethasone, High Dose Methotrexate (IM) < 10 Years | 14 |
| Prednisone, Capizzi Methotrexate <10 Years | 16 |
| Prednisone, Capezzi Methotrexate >= 10 Years | 95 |
| Prednisone and High Dose Methotrexate < 10 Yrs Old | 17 |
| Prednisone and High Dose Methotrexate >=10 Years | 98 |
| Dexamethasone, High Dose Methotrexate (IM) >= 10 Years | 39 |
| Prednisone, Capezzi Methotrexate (Down's Syndrome) | 3 |
| Dexamethasone, Capizzi Methotrexate Down Syndrome (Non Random) | 3 |
| Prednisone and High Dose Methotrexate (Non Randomly Assigned) | 3 |
Bone marrow MRD status is defined as negative with < 0.1 detectable leukemia cells. (NCT00075725)
Timeframe: 5 years
| Intervention | percentage of participants (Number) |
|---|---|
| Dexamethasone and Capizzi Methotrexate Patients < 10 Years | 86.4 |
| Dexamethasone, High Dose Methotrexate (Non Randomly Assigned) | 93.6 |
| Dexamethasone & Capizzi Methotrexate Patients => 10 Years Old | 80.5 |
| Dexamethasone, High Dose Methotrexate (IM) < 10 Years | 93.1 |
| Prednisone, Capizzi Methotrexate <10 Years | 86.5 |
| Prednisone, Capezzi Methotrexate >= 10 Years | 83.4 |
| Prednisone and High Dose Methotrexate < 10 Yrs Old | 84.2 |
| Prednisone and High Dose Methotrexate >=10 Years | 83.9 |
| Dexamethasone, High Dose Methotrexate (IM) >= 10 Years | 85.3 |
| Prednisone, Capezzi Methotrexate (Down's Syndrome) | 74.4 |
| Dexamethasone, Capizzi Methotrexate Down Syndrome (Non Random) | 25 |
Bone marrow MRD status is defined as negative with < .01 detectable leukemia cells. (NCT00075725)
Timeframe: 5 years
| Intervention | percentage of participants (Number) |
|---|---|
| Dexamethasone and Capizzi Methotrexate Patients < 10 Years | 95.4 |
| Dexamethasone, High Dose Methotrexate (Non Randomly Assigned) | 92.9 |
| Dexamethasone & Capizzi Methotrexate Patients => 10 Years Old | 87.4 |
| Dexamethasone, High Dose Methotrexate (IM) < 10 Years | 98.1 |
| Prednisone, Capizzi Methotrexate <10 Years | 93.3 |
| Prednisone, Capizzi Methotrexate >= 10 Years | 90.2 |
| Prednisone and High Dose Methotrexate < 10 Yrs Old | 94.5 |
| Prednisone and High Dose Methotrexate >=10 Years | 90.5 |
| Dexamethasone, High Dose Methotrexate (IM) >= 10 Years | 91.6 |
| Prednisone, Capizzi Methotrexate (Down's Syndrome) | 78.3 |
| Dexamethasone, Capizzi Methotrexate Down Syndrome (Non Random) | 25.0 |
Bone marrow MRD status is defined as positive with >= 0.1 detectable leukemia cells. (NCT00075725)
Timeframe: 5 years
| Intervention | percentage of participants (Number) |
|---|---|
| Dexamethasone and Capizzi Methotrexate Patients < 10 Years | 66.5 |
| Dexamethasone, High Dose Methotrexate (Non Randomly Assigned) | 43.3 |
| Dexamethasone & Capizzi Methotrexate Patients => 10 Years Old | 35.4 |
| Dexamethasone, High Dose Methotrexate (IM) < 10 Years | 80 |
| Prednisone, Capizzi Methotrexate <10 Years | 34.7 |
| Prednisone, Capizzi Methotrexate >= 10 Years | 39 |
| Prednisone and High Dose Methotrexate < 10 Yrs Old | 55 |
| Prednisone and High Dose Methotrexate >=10 Years | 47.8 |
| Dexamethasone, High Dose Methotrexate (IM) >= 10 Years | 49.4 |
Bone marrow MRD status is defined as positive with >= 0.1 detectable leukemia cells, and negative with < 0.1 detectable leukemia cells. (NCT00075725)
Timeframe: 5 Years
| Intervention | percentage of participants (Number) |
|---|---|
| Dexamethasone and Capizzi Methotrexate Patients < 10 Years | 79.2 |
| Dexamethasone, High Dose Methotrexate (Non Randomly Assigned) | 69.9 |
| Dexamethasone & Capizzi Methotrexate Patients => 10 Years Old | 65.6 |
| Dexamethasone, High Dose Methotrexate (IM) < 10 Years | 86.2 |
| Prednisone, Capizzi Methotrexate <10 Years | 93.8 |
| Prednisone, Capizzi Methotrexate >= 10 Years | 63.1 |
| Predisone and High Dose Methotrexate < 10 Yrs Old | 84.2 |
| Prednisone and High Dose Methotrexate >=10 Years | 73.6 |
| Dexamethasone, High Dose Methotrexate (IM) >= 10 Years | 74.6 |
5 reviews available for prednisone and Minimal Disease, Residual
| Article | Year |
|---|---|
Role of Radiation Therapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Guidelines from the International Lymphoma Radiation Oncology Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dose Fractionation, Radiation; Dox | 2018 |
Transplantation for mantle cell lymphoma: is it the right thing to do?
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, | 2013 |
[Current treatment of pediatric acute lymphoblastic leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzamides; Child, Preschool; Clinical Trials as Top | 2014 |
Clinical Management Updates in Mantle Cell Lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2016 |
Hematopoietic stem cell transplants for multiple myeloma.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bone Marro | 1996 |
29 trials available for prednisone and Minimal Disease, Residual
| Article | Year |
|---|---|
Adolescent and young adult acute lymphoblastic leukemia. Final results of the phase II pediatric-like GIMEMA LAL-1308 trial.
Topics: Adolescent; Adult; Allografts; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Combine | 2021 |
Reduced-Intensity Delayed Intensification in Standard-Risk Pediatric Acute Lymphoblastic Leukemia Defined by Undetectable Minimal Residual Disease: Results of an International Randomized Trial (AIEOP-BFM ALL 2000).
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cy | 2018 |
Reduced-Intensity Delayed Intensification in Standard-Risk Pediatric Acute Lymphoblastic Leukemia Defined by Undetectable Minimal Residual Disease: Results of an International Randomized Trial (AIEOP-BFM ALL 2000).
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cy | 2018 |
Reduced-Intensity Delayed Intensification in Standard-Risk Pediatric Acute Lymphoblastic Leukemia Defined by Undetectable Minimal Residual Disease: Results of an International Randomized Trial (AIEOP-BFM ALL 2000).
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cy | 2018 |
Reduced-Intensity Delayed Intensification in Standard-Risk Pediatric Acute Lymphoblastic Leukemia Defined by Undetectable Minimal Residual Disease: Results of an International Randomized Trial (AIEOP-BFM ALL 2000).
Topics: Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cy | 2018 |
Expression of CD56 defines a distinct subgroup in childhood T-ALL with inferior outcome. Results of the ALL-BFM 2000 trial.
Topics: Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; CD13 Antigens; CD56 An | 2018 |
Potential loss of prognostic significance of minimal residual disease assessment after R-CHOP-based induction in elderly patients with mantle cell lymphoma in the era of rituximab maintenance.
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherap | 2018 |
Evaluation of Intense Androgen Deprivation Before Prostatectomy: A Randomized Phase II Trial of Enzalutamide and Leuprolide With or Without Abiraterone.
Topics: Adenocarcinoma; Adult; Aged; Androgen Antagonists; Androstenes; Antineoplastic Combined Chemotherapy | 2019 |
[Molecular genetic detection of minimal residual disease (MRD) in children with acute lymphoblastic leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Cyclophosphamide; Cytarabine; D | 2013 |
Lineage classification of childhood acute lymphoblastic leukemia according to the EGIL recommendations: results of the ALL-BFM 2000 trial.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cell Lineage; Child; Child | 2013 |
Methodological aspects of minimal residual disease assessment by flow cytometry in acute lymphoblastic leukemia: A French multicenter study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow; Child; Daunorubici | 2015 |
Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; D | 2015 |
Relapse analysis of irradiated patients within the HD15 trial of the German Hodgkin Study Group.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Cycloph | 2015 |
Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children's Oncology Group study AALL0232.
Topics: Antineoplastic Agents; Asparaginase; Child; Child, Preschool; Dexamethasone; Disease-Free Survival; | 2015 |
Phenotypic and genomic analysis of multiple myeloma minimal residual disease tumor cells: a new model to understand chemoresistance.
Topics: Aged; Bortezomib; Cell Adhesion Molecules; Dexamethasone; Disease Progression; Down-Regulation; Drug | 2016 |
Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined Modali | 2016 |
Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined Modali | 2016 |
Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined Modali | 2016 |
Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Combined Modali | 2016 |
Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological | 2016 |
Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological | 2016 |
Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological | 2016 |
Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological | 2016 |
Minimal residual disease is an important predictive factor of outcome in children with relapsed 'high-risk' acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 2008 |
Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Dise | 2008 |
CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy.
Topics: Adolescent; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineop | 2008 |
CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy.
Topics: Adolescent; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineop | 2008 |
CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy.
Topics: Adolescent; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineop | 2008 |
CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy.
Topics: Adolescent; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineop | 2008 |
Prognostic relevance of dic(9;20)(p11;q13) in childhood B-cell precursor acute lymphoblastic leukaemia treated with Berlin-Frankfurt-Münster (BFM) protocols containing an intensive induction and post-induction consolidation therapy.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 2010 |
Augmented therapy improves outcome for pediatric high risk acute lymphocytic leukemia: results of Children's Oncology Group trial P9906.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 2011 |
Prediction of outcome by early bone marrow response in childhood acute lymphoblastic leukemia treated in the ALL-BFM 95 trial: differential effects in precursor B-cell and T-cell leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Biomarkers; Bone Marrow; Child; Child, | 2012 |
Activating NOTCH1 mutations predict favorable early treatment response and long-term outcome in childhood precursor T-cell lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Asparag | 2006 |
A Contribution to solve the problem of the need for consolidative radiotherapy after intensive chemotherapy in advanced stages of Hodgkin's lymphoma--analysis of a quality control program initiated by the radiotherapy reference center of the German Hodgki
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modalit | 2007 |
Survival and prognostic factors following radiation and/or chemotherapy for primitive neuroectodermal tumors of the pineal region in infants and children: a report of the Childrens Cancer Group.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Child; Child, Pr | 1995 |
Late intensification therapy in adult acute lymphoid leukemia: long-term follow-up of the Southeastern Cancer Study Group experience.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 1994 |
Monitoring bulky mediastinal disease with gallium-67, CT-scan and magnetic resonance imaging in Hodgkin's disease and high-grade non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Ther | 1996 |
Maintenance of remission with human recombinant interferon alfa-2a in patients with stages III and IV low-grade malignant non-Hodgkin's lymphoma. European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide | 1998 |
Value of autologous stem cell transplantation with purged bone marrow as first-line therapy for follicular lymphoma with high tumor burden: a GOELAMS phase II study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Marrow Purging; Cispl | 2000 |
High-dose therapy and autologous bone marrow transplantation for follicular lymphoma in first complete or partial remission: results of a phase II clinical trial.
Topics: Actuarial Analysis; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantati | 2001 |
Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined | 2002 |
43 other studies available for prednisone and Minimal Disease, Residual
| Article | Year |
|---|---|
PH negative acute lymphoblastic leukemia in adolescents and young adults treated according a MRD adapted BFM ALL IC 2009 protocol: Argentine real-world data on 171 patients.
Topics: Disease-Free Survival; Humans; Multicenter Studies as Topic; Neoplasm, Residual; Precursor Cell Lymp | 2023 |
Reduced-dose intensity therapy for pediatric lymphoblastic leukemia: long-term results of the Recife RELLA05 pilot study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 2020 |
Minimal residual disease analysis in childhood mature B-cell leukaemia/lymphoma treated with AIEOP LNH-97 protocol with/without anti-CD20 administration.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 2020 |
Comparison of real-world treatment patterns in chronic lymphocytic leukemia management before and after availability of ibrutinib in the province of British Columbia, Canada.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; British Col | 2020 |
Results of two consecutive treatment protocols in Polish children with acute lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Antineoplastic Protocols; Asparaginase; Child; Child | 2020 |
Reduced intensity of early intensification does not increase the risk of relapse in children with standard risk acute lymphoblastic leukemia - a multi-centric clinical study of GD-2008-ALL protocol.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cyclophosphamid | 2021 |
Ponatinib-Induced Graft-versus-Host Disease/Graft-versus-Leukemia Effect in a Patient with Philadelphia-Positive Acute Lymphoblastic Leukemia without the T315I Mutation Relapsing after Allogeneic Transplant.
Topics: Adenine Nucleotides; Adult; Arabinonucleosides; Bone Marrow; Clofarabine; Cyclophosphamide; Disease- | 2017 |
Clinical utility of miR-143/miR-182 levels in prognosis and risk stratification specificity of BFM-treated childhood acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow Cells; Child; | 2018 |
[Relationship between Early Treatment Response and Prognosis in Children with Acute Lymphoblastic Leukemia].
Topics: Child; Disease-Free Survival; Humans; Neoplasm, Residual; Precursor Cell Lymphoblastic Leukemia-Lymp | 2018 |
Risk group assignment differs for children and adults 1-45 yr with acute lymphoblastic leukemia treated by the NOPHO ALL-2008 protocol.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cytogene | 2013 |
[The optimal total focal radiotherapy dosage after first-line chemotherapy in patients with Hodgkin lymphoma].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Dacarbazin | 2012 |
ALL-REZ BFM--the consecutive trials for children with relapsed acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow; Child; Combin | 2013 |
Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cyclopho | 2013 |
[Prognostic Value of Prednisone Response in CCLG-ALL 2008].
Topics: Disease-Free Survival; Humans; Multivariate Analysis; Neoplasm, Residual; Precursor Cell Lymphoblast | 2015 |
Prediction of outcomes by early treatment responses in childhood T-cell acute lymphoblastic leukemia: a retrospective study in China.
Topics: Adolescent; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Ma | 2015 |
Guidelines for the management of diffuse large B-cell lymphoma.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; Cyclophospha | 2016 |
[Outcome of childhood T-cell acute lymphoblastic leukemia: a report of 99 cases].
Topics: Bone Marrow; Child; China; Disease-Free Survival; Flow Cytometry; Humans; Leukocyte Count; Lost to F | 2016 |
Positron Emission Tomography/Computed Tomography Assessment After Immunochemotherapy and Irradiation Using the Lugano Classification Criteria in the IELSG-26 Study of Primary Mediastinal B-Cell Lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Disease Progress | 2017 |
Detection of submicroscopic disease in the bone marrow and unaffected testis of a child with T-cell acute lymphoblastic leukemia who experienced "isolated" testicular relapse.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow; Child; Combined Modality | 2009 |
Optimized adoptive T-cell therapy for the treatment of residual mantle cell lymphoma.
Topics: Animals; Antigens, Neoplasm; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2012 |
Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET.
Topics: Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocols; | 2012 |
Clinical features, early treatment responses, and outcomes of pediatric acute lymphoblastic leukemia in China with or without specific fusion transcripts: a single institutional study of 1,004 patients.
Topics: Antineoplastic Agents, Hormonal; Child; Child, Preschool; China; Cohort Studies; Cytogenetic Analysi | 2012 |
Loss of heterozygosity of p16 correlates with minimal residual disease at the end of the induction therapy in non-high risk childhood B-cell precursor acute lymphoblastic leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Cyclin-Depend | 2002 |
Prospective molecular monitoring of BCR/ABL transcript in children with Ph+ acute lymphoblastic leukaemia unravels differences in treatment response.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Female; Follow- | 2002 |
Evolution of BFM trials for childhood ALL.
Topics: Bone Marrow Transplantation; Child; Child, Preschool; Clinical Trials as Topic; Humans; Infant; Neop | 2004 |
Diffuse large B-cell lymphoma presenting as a sacral tumor. Report of two cases.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2003 |
[Graft-versus-ATLL effect induced by abrupt discontinuation of immunosuppression following allogeneic bone marrow transplantation].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cyclophosphamide; Cyclo | 2005 |
Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.
Topics: Adult; Antineoplastic Agents; Benzamides; Chromosomes, Human, Pair 22; Chromosomes, Human, Pair 9; C | 2005 |
A Bayesian approach to a patient with a residual mass after treatment for non-Hodgkin's lymphoma of the thyroid.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy | 2005 |
Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemo | 2006 |
Low-dose arsenic trioxide sensitizes glucocorticoid-resistant acute lymphoblastic leukemia cells to dexamethasone via an Akt-dependent pathway.
Topics: Antineoplastic Agents; Apoptosis; Arsenic Trioxide; Arsenicals; bcl-Associated Death Protein; Blotti | 2007 |
Aggressive chemotherapy for acute leukemia relapsed after transplantation.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Cyta | 1994 |
Detection of a dormant 20q- leukemia clone in bone marrow cultures with hematopoietic growth factors: implications for secondary leukemia post-transplant.
Topics: Acute Disease; Adult; Anemia, Refractory, with Excess of Blasts; Antimetabolites, Antineoplastic; An | 1997 |
Detectable molecular residual disease at the beginning of maintenance therapy indicates poor outcome in children with T-cell acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Biomarkers, Tumor; Blottin | 1997 |
[The presence of minimal residual disease during induction therapy is a reliable factor for the prognosis of recurrence in children with standard-risk B-cell precursor acute lymphoblastic leukemia].
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Burkitt Lymphoma; Child; Cyclophospham | 1999 |
[Malignant lymphoma: magnetic resonance tomography findings in residual supradiaphragmatic space-occupying lesions].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; | 1999 |
Rapid molecular response during early induction chemotherapy predicts a good outcome in childhood acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow; Child; Child, | 2000 |
When is hilar uptake of 67Ga-citrate indicative of residual disease after CHOP chemotherapy?
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Citrates; Cyclophosphamide; Doxorubicin; Fema | 2000 |
Locoregional irradiation for inflammatory breast cancer: effectiveness of dose escalation in decreasing recurrence.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvan | 2000 |
Molecular and clinical prognostic factors in BFM-treated childhood acute lymphoblastic leukemia patients: a single institution series.
Topics: Adolescent; Aneuploidy; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Biomarkers, Tu | 2000 |
Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; C | 2000 |
The role of molecular monitoring in autotransplantation for non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Marrow; B | 2002 |
Detection of minimal residual disease identifies differences in treatment response between T-ALL and precursor B-ALL.
Topics: Adolescent; Antineoplastic Agents; Child; Child, Preschool; Cohort Studies; Disease-Free Survival; F | 2002 |